Natural History and Management of HFE-hemochromatosis

Eng K. Gan, M.B.B.S.; Lawrie W. Powell, M.B.B.S., M.D., Ph.D., F.R.A.C.P., F.R.C.P.; John K. Olynyk, B.Med.Sc., M.B.B.S., M.D., F.R.A.C.P.

Disclosures

Semin Liver Dis. 2011;31(3):293-301. 

In This Article

Abstract and Introduction

Abstract

Advances in our knowledge of hereditary hemochromatosis (HH) over the past 150 years have revealed new insights into this common genetic disorder. Meticulous family and HLA association studies followed ultimately by cloning of the HFE gene have dramatically changed our understanding of the natural history and manifestations of HH. Cross-sectional studies demonstrated that HH had a highly variable clinical and biochemical penetrance in susceptible individuals of northern European descent. "State-of-the-art" large longitudinal population studies have accurately defined the natural history. We now recognize that HH is not as discreet an entity as previously thought because genetic and environmental modifiers of disease penetrance are increasingly identified as influencing the clinical course of HH. While phlebotomy remains the cornerstone of therapy, our diagnostic approach has been refined to incorporate new biochemical, genetic, and noninvasive methods that complement more traditional approaches. This review aims to encapsulate this new knowledge in a framework that addresses commonly raised issues relating to the current natural history, diagnosis, and management of HH patients.

Introduction

Hereditary hemochromatosis (HH) comprises a group of disorders that can result in progressive iron overload leading to hepatic cirrhosis, primary liver cancer, diabetes mellitus, hypogonadotrophic hypogonadism, joint disease, and cardiomyopathy. Mutations of the HFE gene are responsible for the majority of cases of HH and are common in populations of northern European origin.[1,2] Multiple large population studies in the last two decades have demonstrated that the clinical and biochemical penetrance is highly variable.[3] HH affects ~1 in 200 people of northern European origin, with more than 90% of these cases being caused by homozygosity for the C282Y mutation in the HFE gene product. The variability of natural history and earlier clinical presentations of modern-day HH are attributable to genetic and environmental interactions combined with earlier identification and diagnosis.[4,5]

processing....